AbbVie Q3 2026 Earnings: Diluted EPS More Than Doubles

AbbVie reported robust third-quarter 2026 financial results, with diluted earnings per share on a GAAP basis reaching $2.37, a gain of more than 100 percent compared with the same period a year earlier. Adjusted diluted EPS came in at $3.82, also more than doubling on a year-over-year basis, signaling broad-based profit momentum across the pharmaceutical giant's portfolio.

The results were tempered slightly by a charge related to acquired in-process research and development and milestone expenses, which created an unfavorable impact of $0.11 per share. Such charges are common for large pharmaceutical companies that actively pursue licensing deals and acquisitions to replenish their drug pipelines, and the headwind was modest relative to the overall earnings growth reported.

Read more Okta to Join S&P 500 in November Index Reshuffle →

The more-than-100-percent jump in both GAAP and adjusted EPS reflects the degree to which AbbVie has rebuilt its earnings base following the loss of exclusivity on its flagship immunology drug Humira, which faced biosimilar competition that weighed heavily on prior-period results. The year-over-year comparisons now benefit from that earlier pressure having largely cycled through the financials.

Analysts and investors will likely focus on the sustainability of the rebound, particularly the contributions from newer immunology products and the oncology portfolio, as AbbVie works to diversify revenue streams. The IPR&D and milestone expenses signal continued investment in future growth drivers, a strategic priority the company has emphasized since Humira's exclusivity cliff began.

Continue reading at Earnings.